CF3-MQC

CF3-MQC is an experimental drug developed by Arena Pharmaceuticals, which acts as a reasonably potent and highly selective antagonist for the free fatty acid receptor FFAR3 (GPR41), and is used for research into the function of this receptor.[1][2][3] It is unclear whether CF3-MQC is the same compound as AR399519, the only other synthetic FFAR3 antagonist currently available, as while they are both cited to the same 2006 patent which claims only six closely related example structures as FFAR3 antagonists,[4] the structure of AR399519 is not disclosed in the published sources.[5][6]

## References

1. ↑ "Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets". Frontiers in Endocrinology 3: 111. 2012. doi:10.3389/fendo.2012.00111. PMID 23060857.
2. ↑ "FFA3 Activation Stimulates Duodenal Bicarbonate Secretion and Prevents NSAID-Induced Enteropathy via the GLP-2 Pathway in Rats". Digestive Diseases and Sciences 62 (8): 1944–1952. August 2017. doi:10.1007/s10620-017-4600-4. PMID 28523577.
3. ↑ "Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators". Journal of Medicinal Chemistry 63 (7): 3577–3595. April 2020. doi:10.1021/acs.jmedchem.9b02036. PMID 32141297.
4. ↑ Leonard JN, et al. Gpr41 and modulators thereof for the treatment of insulin-related disorders. WO 2006/052566
5. ↑ "Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells". Molecular Metabolism 2 (4): 376–392. 2013. doi:10.1016/j.molmet.2013.08.006. PMID 24327954.
6. ↑ "The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon". American Journal of Physiology. Gastrointestinal and Liver Physiology 315 (1): G53–G65. July 2018. doi:10.1152/ajpgi.00346.2017. PMID 29494208.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/CF3-MQC. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CF3-MQC&oldid=4032374"